news

CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Monday, September 9, 2019 at 11:40 a.m. EDT.  Institutional […]

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Aug. 1, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update. Total revenues were $4.0 million and net loss was $7.2 million for the three months ended

CUPERTINO, Calif., July 25, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019. Thursday, August 1 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeToll Free:                     877-407-0784International:               201-689-8560Conference

Gilead Also Receives Exclusive Option to License Additional Products for HIV and Hepatitis B CUPERTINO, Calif., July 22, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT’s SABER®

User Fee Goal Date is December 27, 2019 CUPERTINO, Calif., July 17, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT’s full response to the Complete Response Letter (CRL) it previously received from FDA related to POSIMIR® (bupivacaine extended-release solution) is

CUPERTINO, Calif., June 27, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA) related to POSIMIR® (bupivacaine extended-release solution).  The submission is intended to address the issues raised in the CRL and seeks

CUPERTINO, Calif., June 25, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 27, 2019. The Company has also

CUPERTINO, Calif., June 20, 2019 /PRNewswire/ — DURECT Corporation (“DURECT” or the “Company”) (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock

CUPERTINO, Calif., June 18, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the completed cohorts, the Dose Escalation Committee (DEC) has approved commencement

CUPERTINO, Calif., May 16, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer, and Michael H. Arenberg, Chief Financial Officer, will be participating in the 20th Annual B. Riley FBR Institutional Investor Conference, taking place at the Beverly Hilton Hotel, Beverly Hills, CAMay 22-23. B. Riley FBR Institutional Investor